Cargando…

Prevention of cardiovascular complications in patients with Lp(a)-hyperlipoproteinemia and progressive cardiovascular disease by long-term lipoprotein apheresis according to German national guidelines

Lipoprotein(a) (Lp(a)) is an independent cardiovascular risk factor playing a causal role for atherosclerotic cardiovascular disease (CVD). Lipoprotein apheresis (LA) is a safe well-tolerated outpatient treatment to lower LDL-C and Lp(a) by 60–70%, and is the ultimate escalating therapeutic option i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Klingel, Reinhard, Heibges, Andreas, Fassbender, Cordula
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2017
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5352778/ https://www.ncbi.nlm.nih.gov/pubmed/28185214 http://dx.doi.org/10.1007/s11789-017-0082-3

Ejemplares similares

Lipoprotein apheresis results in plaque stabilization and prevention of cardiovascular events: comments on the prospective Pro(a)LiFe study
por: Klingel, Reinhard, et al.
Publicado: (2015)

Clinical benefit of long-term lipoprotein apheresis in patients with severe hypercholesterolemia or Lp(a)-hyperlipoproteinemia with progressive cardiovascular disease
por: Heigl, Franz, et al.
Publicado: (2015)

Lipoprotein(a)-hyperlipoproteinemia as cause of chronic spinal cord ischemia resulting in progressive myelopathy – successful treatment with lipoprotein apheresis
por: Heigl, Franz, et al.
Publicado: (2017)

Impact of the German Lipoprotein Apheresis Registry (DLAR) on therapeutic options to reduce increased Lp(a) levels
por: Schettler, Volker J. J., et al.
Publicado: (2015)

LDL Apheresis and Lp (a) Apheresis: A Clinician’s Perspective
por: Kayikcioglu, Meral
Publicado: (2021)

Influence of metabolic syndrome superposition on familial combined hyperlipoproteinemia cardiovascular complication rate
por: Cicero, Arrigo F.G., et al.
Publicado: (2013)

Why continued lipoprotein apheresis is vital for homozygous familial hypercholesterolemia patients with COVID-19
por: Vuorio, Alpo, et al.
Publicado: (2021)

Primary and secondary prevention of cardiovascular disease in patients with hyperlipoproteinemia (a)
por: Grützmacher, P., et al.
Publicado: (2017)

The German Lipoprotein Apheresis Registry (GLAR) – almost 5 years on
por: Schettler, V. J. J., et al.
Publicado: (2017)

Case of familial hyperlipoproteinemia type III hypertriglyceridemia induced acute pancreatitis: Role for outpatient apheresis maintenance therapy
por: Saleh, Mohannad Abou, et al.
Publicado: (2017)

Why Some Patients Undergoing Lipoprotein Apheresis Therapy Develop New Cardiovascular Events?
por: Julius, Ulrich, et al.
Publicado: (2020)

Increased cardiovascular risk associated with hyperlipoproteinemia (a) and the challenges of current and future therapeutic possibilities
por: Fras, Zlatko
Publicado: (2020)

Familial Hypercholesterolemia and Lipoprotein Apheresis
por: Makino, Hisashi, et al.
Publicado: (2019)

Current Role of Lipoprotein Apheresis
por: Thompson, Gilbert, et al.
Publicado: (2019)

Therapeutic management of hyperlipoproteinemia (a)
por: Kosmas, Constantine E, et al.
Publicado: (2019)

Case report: lipoprotein apheresis reduces the risk of cardiovascular events and prolongs pregnancy in a woman with severely elevated lipoprotein(a), cardiovascular disease, and a high risk of preeclampsia
por: Marlȩga-Linert, Joanna, et al.
Publicado: (2023)

Comparison of plasma separation using centrifugation or filtration for MONET lipoprotein apheresis in patients with cardiovascular disease and severe dyslipidemia
por: Waitz, Grit, et al.
Publicado: (2022)

Lipoprotein(a) Lowering—From Lipoprotein Apheresis to Antisense Oligonucleotide Approach
por: Greco, Maria Francesca, et al.
Publicado: (2020)

Lp(a) and the Risk for Cardiovascular Disease: Focus on the Lp(a) Paradox in Diabetes Mellitus
por: Kostner, Karam M., et al.
Publicado: (2022)

Novel Pharmacological Therapies for the Management of Hyperlipoproteinemia(a)
por: Kosmas, Constantine E., et al.
Publicado: (2023)

Identification and Characterization of Two Novel Compounds: Heterozygous Variants of Lipoprotein Lipase in Two Pedigrees With Type I Hyperlipoproteinemia
por: Wang, Shuping, et al.
Publicado: (2022)

Activation of Lipid Mediator Formation Due to Lipoprotein Apheresis
por: Weylandt, Karsten-H., et al.
Publicado: (2019)

Lipoprotein apheresis efficacy and challenges: single center experience
por: Özdemir, Zehra Narlı, et al.
Publicado: (2022)

The Impact of Lipoprotein Apheresis on Oxidative Stress Biomarkers and High-Density Lipoprotein Subfractions
por: Mickiewicz, Agnieszka, et al.
Publicado: (2020)

Lipoprotein-Associated Phospholipase A2 (Lp-PLA(2)): A Novel and Promising Biomarker for Cardiovascular Risks Assessment
por: Cai, Anping, et al.
Publicado: (2013)

Lp-PLA(2) Inhibitors for the Reduction of Cardiovascular Events
por: Steen, Dylan L., et al.
Publicado: (2013)

Editorial Lp(a) – the underestimated cardiovascular risk factor
por: Mellwig, Klaus-Peter
Publicado: (2017)

Eruptive Xanthomas Caused by Primary Type V Hyperlipoproteinemia
por: Nakamura, Yoshihiro, et al.
Publicado: (2021)

Hyperlipoproteinemia(a) and Severe Coronary Artery Lesion Types
por: Ilina, Larisa N., et al.
Publicado: (2022)

Diet and Lp(a): Does Dietary Change Modify Residual Cardiovascular Risk Conferred by Lp(a)?
por: Enkhmaa, Byambaa, et al.
Publicado: (2020)

Lipoprotein-apheresis reduces circulating microparticles in individuals with familial hypercholesterolemia
por: Connolly, Katherine D., et al.
Publicado: (2014)

Current Role of Lipoprotein Apheresis in the Treatment of High-Risk Patients
por: Julius, Ulrich
Publicado: (2018)

Long-term lipoprotein apheresis in the treatment of severe familial hypercholesterolemia refractory to high intensity statin therapy: Three year experience at a lipoprotein apheresis center
por: Mickiewicz, Agnieszka, et al.
Publicado: (2020)

Study of lipoprotein(a) and its impact on atherosclerotic cardiovascular disease: Design and rationale of the Mass General Brigham Lp(a) Registry
por: Berman, Adam N., et al.
Publicado: (2020)

A rare case of COVID-19 pneumonia with severe hyperlipoproteinemia
por: Shimoda, Masafumi, et al.
Publicado: (2022)

A Case of Type V Hyperlipoproteinemia Resistant to Insulin Treatment
por: Mangeshkar, Shaunak, et al.
Publicado: (2023)

Lipoprotein apheresis in the management of severe hypercholesterolemia and of elevation of lipoprotein(a): current perspectives and patient selection
por: Julius, Ulrich
Publicado: (2016)

The expanding role of lipoprotein apheresis in the treatment of raised lipoprotein(a) in ischaemic heart disease and refractory angina
por: Khan, Tina Z, et al.
Publicado: (2014)

Use of CMR imaging to assess the effect of lipoprotein apheresis in patients with refractory angina and raised lipoprotein(a)
por: Khan, Tina, et al.
Publicado: (2015)

Association between lipoprotein(a) (Lp(a)) levels and Lp(a) genetic variants with coronary artery calcification
por: Pechlivanis, Sonali, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_30k30at91j7p66lqk7ek92pfu6